Abstract

Dendritic cell (DC) immunotherapy has been used to treat various types of tumors. Although it is already in use in clinical practice, the mechanisms through which it acts need clarification. In addition, the processes used to obtain DCs need to be improved so that more effective treatments can be offered. In this article, we present an update on the application of DC immunotherapy and the patents involved in the process.